Skinbiotherapeutics Share Discussion Threads

[bobalot] 11/12/2017 09:48

minimising THE FABLED AND MISLED FREE SHARE ISSUE THAT ATTRACTS TWO TAXES--OPTI HAS BEEN HYPED ON LIES ABOUT FREE SHARES...hahaha I sold out of OPTI because their business model is basically flawed --- asking 50% of revenues from partners will not make OPTI products world beaters imo.

Hence, no irony....lol...just reality of business deals behaviour.

[f3rdinand] 11/12/2017 09:39

The hilarious irony is that he's probably the only SBTX holder that hasn't got any OPTI shares... his deramping of OPTI is in effect talking down his own SBTX holding!

[bobalot] 11/12/2017 09:15

The business is in the company of a leading edge researcher who wins awards for her work.

CEO Cath O'Neill named one of this years 50 female Movers and Shakers in the UK healthcare industry

CEO Cath O’Neill named one of this years 50 female Movers and Shakers in the UK healthcare industry by @BioBeatUK.

The annual report aims to celebrate exceptional female leaders and bioentrepreneurs who are driving innovative thinking within the industry.

Cath has been recognised for her outstanding research into skin health as well as spearheading the success of SkinBioTherapeutics
2nd November, 2017





loungeact ---- 11 Dec '17 - 09:28 - 1154 of 1154 0 0 (Filtered)
A THREAD RODENT/ TROLL

[bobalot] 11/12/2017 09:13

HERE IS A KEYSTONE ANNOUNCEMENT ABOUT HEALTH AND SAFETY APPROVAL AND ANNOUNCES THE START OF HUMAN TESTING EARLY 2018...the testing only takes a month, so selling the stuff next year through a major brand name will happen imo.


SkinBiotix® platform passes additional external toxicity tests

SkinBiotix® platform passes additional external toxicity tests.
Scientific progress on track.

Manchester, UK – 9 November 2017 - SkinBioTherapeutics plc (AIM: SBTX, the “Company”;), a life science company focused on skin health, has passed two additional and final third party cellular toxicity tests for its SkinBiotix® technology.

The in vitro tests, for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells), follow on from the recent first stage cytotoxicity tests, as announced on 3 October 2017.

The studies were again conducted by Charles River Laboratories, a Contract Research Organisation (CRO), in accordance with the OECD Principles of Good Laboratory Practice.

In the photo-toxicity test, the testers were looking to determine whether the SkinBiotix® technology would become toxic to cells when exposed to UV and visible light. The results showed that SkinBiotix® is non-phototoxic.

The second test, for ocular toxicity, was carried out to determine whether SkinBiotix® is toxic to eye cells. This involved measuring for two important components which are predictive of irritation, corneal opacity (cloudiness) and permeability (ability to let fluids pass through the eye). The SkinBiotix® technology also passed this test.

SkinBioTherapeutics will continue developing the technology towards the three applications in skin care, anti-infection and skin repair.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented:

“Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy."

“With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets."

“We are continuing formulation development and are confident about starting our human studies in 2018.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

[bobalot] 11/12/2017 09:10

HER IS THE FIRST INTERNATIONAL PATENT --- many others will follow on very soon.


Notification of first patent grant

Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.

The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company's first patent to progress to grant from within its portfolio of patents pending estate.

The patent, numbered 2013246701 and entitled 'Probiotic bacteria', runs until 15 March 2033.
The patent is in active prosecution in other locations worldwide including Europe, USA and China.

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix® patent family underpins the commercial potential worldwide.
"This is a step forward in preparing for human trials, which are scheduled for 2018."

4th December, 2017

[bobalot] 11/12/2017 09:09

the following is a recap of recent news for new investors to understand this company will commercialise its products next year to generate high value revenues from the startng gate.

[bobalot] 11/12/2017 09:07

loungeact 11 Dec '17 - 08:55 - 1148 of 1148 0 0 (Filtered)

YOU DENEGRATE YOURSELF WITH SUCH BLATENT IGNORANCE.

[bobalot] 10/12/2017 16:28

Following on from the first international patent award selling the cosmetic and clinical creams in the EU, China and America is most definitely on the cards, post patent registration next year. Those are the largest markets in the world and they happen to be upwardly mobile with a middle class population in excess of 150 - 500 million respectively.


SBTX is planning global distribution through a big brand name imo.

The patents registration is in active prosecution in other locations worldwide including Europe, USA and China.

They all equate to the largest and most affluent population centres.

Everything is looking good so far for SBTX clinical and cosmetic creams imo....just wait for the price inflexions to happen.

loungeact 10 Dec '17 - 16:56 - 1147 of 1147 0 0 (Filtered)

THE THREAD OPTI DIPSTICKER

[bobalot] 10/12/2017 10:20

slartybartfaster 9 Dec '17 - 10:33 - 1143 of 1144 0 0 (Filtered)
loungeact 9 Dec '17 - 14:36 - 1144 of 1144 5 0 (Filtered)

UNTTER NONSENSE FROM THE OPTI RAMPING DEPT...lol

[bobalot] 08/12/2017 22:47

riskybusiness1 8 Dec '17 - 19:13 - 1138 of 1141 1 0

opti cashed out of SBTX and own no patents/IP...JUST STOCK THAT THEY PLAN TO GIVE AWAY AS A DIVI...as said before OPTI is depleting its value for OPTI PI's.

OPTI would have served its PI's far better by not selling off SBTX so early, six months from now the stock could easily double in value. But it was a great idea to get tech to market from a UNI project that might have never seen the light of day. In that sense, SOH is a real visionary for useful, marketable ideas.


SBTX investors are much better positioned to get a high return...but you believe the OPTI HYPE pedalled by its gurus as its real terms equity value depletes ...lol@opti mob.



elrico 8 Dec '17 - 20:05 - 1141 of 1142 1 0 (Filtered)

permanently filtered.

[elrico] 08/12/2017 20:05

Risky - Explained in the most simple terms even one braincell would suffice in order to understanding. Sadly, in Bob's case...

Slarty - You do Risky a disservice.

[riskybusiness1] 08/12/2017 19:21

To spell it out...42% of £11m is worth MORE than 52% worth £250k.Do you or do you not agree?Opti diluted its SKIN holding so SKIN could raise money to build value. It could have kept SKIN in Opti but did not want to raise money and dilute Opti.Owning 100% of IP and having no money to do anything is pointless.

[slartybartfaster] 08/12/2017 19:15

Bob you really are tool. First you call the most authorative of both opti and sbtx a con artist and now you call the next in line for the thrown an idiot. If riskybusiness had the same access to soh you wouldnt be able to split risky and elrico for their research and knowledge.

[riskybusiness1] 08/12/2017 19:13

BUT OPTI PAID £250k FOR 52% OF THOSE PATENTS A YEAR BEFORE THE IPO.

[bobalot] 08/12/2017 18:17

BUT THEY LOST THE WORTH OF THE PATENTS about another 7.5 million...so the majority equity worth of SBTX has been lost by OPTI because of the float -- hence OPTI's value is depleted, they are left with 41% imo. The stock would have been worth far more going into the future with three groundbreaking skin treatments if the float had been avoided, OPTI holders might have been short changed for short term gain.

RISKY you are the real idiot in the room --- in denial believing the OPTI MOB.

At todays market valuation the MCAP is about 9 million, at 10-11p about 12 million which is the average this year...growth next year expected to be around +40%+.

Smell the coffee.

9.11 -0.39 (-4.09%)
Dec 8 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted

Range 9.00 - 9.50
52 week 9.00 - 17.75
Open 9.30
Vol / Avg. 333,254.00/213,003.00
Mkt cap 9.26M*

[riskybusiness1] 08/12/2017 17:28

Bob Opti bought its entire holding of Skin for £650k and made a £5m paper profit within a year. Clearly without the £4m skin raised for ipo it was not worth £11m. Your really are an idiot if you think Opti listed a division worth £11m retaining a £5m holding.

[shazbo] 08/12/2017 16:17

Vast majority off loading these past few weeks. Nothing moving this for probably years Bob. You might get a little lift with some test results then another three years of drifting agonisingly downwards before revenues. Hang on for 5p for any top ups. Renaming it Slidy McSlidington.

[bobalot] 08/12/2017 14:52

OneDayRodders 8 Dec '17 - 14:34 - 1131 of 1131 1 0

FROM THE OPTI MOB...lol